Inovio: DNA Vaccine pusher

Inovio’s proprietary platform is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual’s immune system to generate a robust targeted T cell and antibody response. Inovio’s technology has generated impressive results in preclinical and clinical studies. VGX-3100, a product using the platform technology, has entered Phase 3 trials as the first immunotherapy for HPV-related cervical precancer.

https://www.inovio.com/about/

INO-Charthttp://ir.inovio.com/investors/stock-information/default.aspx

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s